title: A clearer view of evidence in treating macular degeneration: off-label policies and independent research.
authors.affiliation: Drug Evaluation Area, Regional Agency for Health and Social Care, Bologna, Italy.
authors.forename: Giulio
authors.initials: G
authors.lastname: Formoso
authors.forename: Anna Maria
authors.initials: AM
authors.lastname: Marata
authors.forename: Nicola
authors.initials: N
authors.lastname: Magrini
authors.forename: Lisa
authors.initials: L
authors.lastname: Bero
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000191:economics* / Q000627:therapeutic use; D000068258:Bevacizumab; D004345:Drug Industry / Q000191:economics* / Q000331:legislation & jurisprudence; D005060:Europe; D005252:Fees, Pharmaceutical; D006801:Humans; D007558:Italy; D008268:Macular Degeneration / Q000188:drug therapy*; D056687:Off-Label Use / Q000191:economics* / Q000331:legislation & jurisprudence; D016032:Randomized Controlled Trials as Topic; D000069579:Ranibizumab; D012196:Review Literature as Topic; D014481:United States
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000069579:Ranibizumab